Review
Pharmacology & Pharmacy
Matthew D. Kerr, David A. McBride, Arun K. Chumber, Nisarg J. Shah
Summary: A deeper understanding of the immunostimulatory properties of cytoreductive therapies has supported their utility in combination therapies involving cancer vaccines to induce a durable anti-tumor immune response. Combination therapies may have synergies depending on the identity of the cytotoxic agent, vaccine target, dosing schedule, and cancer type, suggesting that combining cancer vaccines with immunomodulatory cytoreductive therapy is a promising strategy for cancer therapy.
EXPERT OPINION ON DRUG DISCOVERY
(2021)
Article
Oncology
Alessio Amatu, Arianna Pani, Giorgio Patelli, Oscar M. Gagliardi, Marina Loparco, Daniele Piscazzi, Andrea Cassingena, Federica Tosi, Silvia Ghezzi, Daniela Campisi, Renata Grifantini, Sergio Abrignani, Salvatore Siena, Francesco Scaglione, Andrea Sartore-Bianchi
Summary: This study evaluated the seroconversion rate of anti-spike antibodies in solid tumor patients after receiving SARS-CoV-2 mRNA vaccines and found a lower conversion rate in cancer patients. Age and treatment type also had an impact on the conversion rate. It is suggested to consider enhanced vaccination strategies for this group of patients and closely monitor SARS-CoV-2 infection during treatment.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Pharmacology & Pharmacy
Fatemeh Zahedipour, Parvin Zamani, Khadijeh Jamialahmadi, Mahmoud Reza Jaafari, Amirhossein Sahebkar
Summary: Angiogenesis plays a significant role in the metastasis and progression of melanoma. Vaccines targeting angiogenesis in melanoma, including specific immunotherapy, show promise in inducing strong anti-tumor immune responses by targeting genetically stable endothelial cells. Various types of vaccines, such as DNA, peptide, protein, dendritic cell-based, and endothelial cell vaccines, have been studied to target angiogenesis in melanoma for potential progress in developing effective treatments.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Editorial Material
Engineering, Biomedical
Andrew Redenti, Jaeseung Hahn, Tal Danino
Summary: Flagellated bacteria coated with antigen-adsorbing nanoparticles can induce systemic antitumour immune responses by transporting tumour antigens towards the tumour periphery, where they are taken up by functional antigen-presenting cells.
NATURE BIOMEDICAL ENGINEERING
(2022)
Review
Oncology
Nirjari Kothari, Humzah Postwala, Aanshi Pandya, Aayushi Shah, Yesha Shah, Mehul R. Chorawala
Summary: Cancer immunotherapy, particularly cancer vaccine therapy, holds promise in improving outcomes in cancer treatment. However, individually they may not result in substantial tumor eradication. Combination of cancer vaccines with chemotherapeutic agents has shown potential in intensifying anti-tumor activities by stimulating the immune response. This review summarizes the mechanisms of cancer vaccines, their interactions with chemotherapy, and future directions.
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Jeroen Heuts, Wim Jiskoot, Ferry Ossendorp, Koen van der Maaden
Summary: Cationic nanoparticles have shown to be effective in cancer immunotherapy by delivering tumor-associated antigens to dendritic cells and inducing strong antigen-specific cellular immune responses. Lipid- and polymer-based cationic nanoparticles are utilized for different types of cancer vaccines, and their potential in T-cell induction is discussed for therapeutic cancer vaccination.
Article
Oncology
Agnieszka Szczygiel, Natalia Anger-Gora, Katarzyna Wegierek-Ciura, Jagoda Mierzejewska, Joanna Rossowska, Tomasz M. Goszczynski, Marta switalska, El(z) over dotbieta Pajtasz-Piasecka
Summary: The study found that the nanoconjugate HES-MTX has greater immunomodulatory potential than MTX, leading to significant tumor growth inhibition and activation of a systemic specific antitumor response.
Article
Chemistry, Multidisciplinary
Yiran Zheng, Zhiyuan Zhong
Summary: Cancer vaccines have become powerful and clinically viable therapeutic modalities for reducing tumor burden, eradicating residual cancer cells, and preventing relapse. Recent years have seen rapid advancements in next-generation cancer vaccines, with cutting-edge technologies focused on eliciting robust and durable immune responses specific to cancer, as well as reducing systemic side effects. This perspective highlights innovative strategies such as high-throughput screening for neoantigens and optimal delivery systems, knowledge-based de novo design of effective delivery platforms with tissue-targeting specificity, and synergizing cancer vaccines with clinical immunotherapeutic practices like CAR-T and anti-PD-1 therapies.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Oncology
G. Spitaleri, P. Trillo Aliaga, C. Catania, E. Del Signore, I. Attili, C. Santoro, F. Giugliano, P. P. M. Berton Giachetti, G. . Curigliano, A. Passaro, F. de Marinis
Summary: This prospective trial examined the safety of COVID-19 vaccines in patients with thoracic cancer receiving anticancer treatments. The results showed no safety concerns and a low rate of vaccine-related adverse events. The study supports prioritizing vaccination for lung cancer patients undergoing active treatment.
CLINICAL LUNG CANCER
(2023)
Review
Chemistry, Multidisciplinary
Yang Bo, Hua Wang
Summary: Cancer immunotherapies, including therapeutic cancer vaccines, have revolutionized cancer treatment. However, the limited efficacy of cancer vaccines, especially for immunologically cold solid tumors, remains a challenge. In situ cancer vaccines, particularly biomaterials-based vaccines, have emerged as a promising approach to address this challenge by generating endogenous antigens directly from tumors. This review provides an overview of biomaterials-based in situ cancer vaccines, discussing their design criteria and potential applications.
ADVANCED MATERIALS
(2023)
Review
Cell Biology
Shan Zhou, Chunmei Fan, Zhaoyang Zeng, Ken H. Young, Yong Li
Summary: Immunotherapy, such as immune checkpoint blockade and chimeric antigen receptor T cells, offers a promising approach to treating cancer. Targeting p53 through therapeutic cancer vaccines has shown progress in clinical trials, indicating potential therapeutic benefits.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Zaoqu Liu, Jinxiang Lv, Qin Dang, Long Liu, Siyuan Weng, Libo Wang, Zhaokai Zhou, Ying Kong, Huanyun Li, Yilin Han, Xinwei Han
Summary: Immunotherapy treatments using the immune system have revolutionized personalized medicine and brought significant benefits for cancer patients. Tumor neoantigens, arising from somatic mutations and presented by major histocompatibility complex, play a crucial role in immunotherapy. With advancements in sequencing technology and bioinformatics, the identification of neoantigens has accelerated and is expected to be integrated into clinical practice. Neoantigen vaccines, such as peptides, DNA, RNA, and dendritic cells, have shown great potential in activating specific T cells and enhancing anti-tumor immunity. This review discusses the origin and prediction of neoantigens, compares different types of neoantigen vaccines, and explores strategies for improving their efficacy, while addressing the challenges in their application.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
David Reparaz, Marta Ruiz, Diana Llopiz, Leyre Silva, Enric Vercher, Belen Aparicio, Josune Egea, Ibon Tamayo-Uria, Sandra Hervas-Stubbs, Jorge Garcia-Balduz, Carla Castro, Mercedes Inarrairaegui, Maria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, Luigi Buonaguro, Charlotte Rohrer, Kathrin Heim, Catrin Tauber, Maike Hofmann, Robert Thimme, Bruno Sangro, Pablo Sarobe
Summary: Immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies may be generated in hepatocellular carcinoma tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Wenqing Jia, Tao Zhang, Haiyan Huang, Haoran Feng, Shaodong Wang, Zichao Guo, Zhiping Luo, Xiaopin Ji, Xi Cheng, Ren Zhao
Summary: This review provides a brief summary of different categories of colorectal cancer (CRC) vaccines and presents current outcomes of relevant clinical trials. It particularly focuses on recent advances in nanovaccines and neoantigen vaccines, which represent the trend and emphasis in CRC vaccine development.
FRONTIERS IN IMMUNOLOGY
(2022)
